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Introduction: Spontaneous intracerebral hemorrhage (ICH) is one of leading causes of mortality and morbidity
worldwide. Several predictive models have been developed for ICH; however, none of them have been consistently
used in routine clinical practice or clinical research. In the study, we aimed to develop and validate a risk score for
predicting 1-year functional outcome after ICH (ICH Functional Outcome Score, ICH-FOS). Furthermore, we
compared discrimination of the ICH-FOS and 8 existing ICH scores with regard to 30-day, 3-month, 6-month,
and 1-year functional outcome and mortality after ICH.
Methods: The ICH-FOS was developed based on the China National Stroke Registry, in which eligible patients were
randomly divided into derivation (60%) and validation (40%) cohorts. Poor functional outcome was defined as
modified Rankin Scale score (mRS) ≥3 at 1 year after ICH. Multivariable logistic regression was performed to
determine independent predictors, and β-coefficients were used to generate scoring system of the ICH-FOS. The
area under the receiver operating characteristic curve (AUROC) and Hosmer-Lemeshow goodness-of-fit test were
used to assess model discrimination and calibration.
Results: The overall 1-year poor functional outcome (mRS ≥ 3) was 46.7% and 44.9% in the derivation (n = 1,953)
and validation (n = 1,302) cohorts, respectively. A 16-point ICH-FOS was developed from the set of independent
predictors of 1-year poor functional outcome after ICH including age (P < 0.001), admission National Institutes of
Health Stroke Scale score (P < 0.001), Glasgow Coma Scale score (P < 0.001), blood glucose (P = 0.002), ICH location
(P < 0.001), hematoma volume (P < 0.001), and intraventricular extension (P < 0.001). The ICH-FOS showed good
discrimination (AUROC) in the derivation (0.836, 95% CI: 0.819-0.854) and validation (0.830, 95% CI: 0.808-0.852)
cohorts. The ICH-FOS was well calibrated (Hosmer-Lemeshow test) in the derivation (P = 0.42) and validation
(P = 0.39) cohort. When compared to 8 prior ICH scores, the ICH-FOS showed significantly better discrimination
with regard to 1-year functional outcome and mortality after ICH (all P < 0.0001). Meanwhile, the ICH-FOS also
demonstrated either comparable or significantly better discrimination for poor functional outcome and mortality
at 30-day, 3-month, and 6-month after ICH.
Conclusion: The ICH-FOS is a valid clinical grading scale for 1-year functional outcome after ICH. Further validation of
the ICH-FOS in different populations is needed.* Correspondence: yongjunwang1962@gmail.com
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Spontaneous intracerebral hemorrhage (ICH) accounts
for 10% to 15% of all strokes and is one of the leading
causes of stroke related mortality and morbidity world-
wide [1-4]. Despite advances in medical knowledge,
treatment for ICH remains strictly supportive. Debate
continues over the development of a standardized and
widely accepted clinical grading scale and outcome pre-
diction model for ICH [5].
Several predictive models have been developed for
ICH [6-16]; however, none of them have been consist-
ently used in routine clinical practice or clinical research
[5]. Moreover, the existing ICH scores were mainly
designed for short-term (in-hospital or 30 days after
ICH) [6-8,10,13-16] or intermediate-term (three months
after ICH) [9,11] outcome prediction. Studies have
shown that a substantial proportion of ICH patients
continue to improve throughout the first year after ICH
[17]. Although a few risk scores were developed [8,12]
or reevaluated [17] for predicting long-term (six months
or one year after ICH) functional outcome after ICH,
they were not sufficiently validated.
In the present study, we aimed to develop and validate
a risk score (ICH Functional Outcome Score, ICH-FOS)
for predicting poor functional outcome at one year after
ICH. Furthermore, we compared discrimination of the
ICH-FOS and existing ICH scores with regard to 30-day,
3-month, 6-month, and 1-year poor functional outcome
and mortality after ICH.
Materials and methods
Study population
The derivation and validation cohort originated from the
largest stroke registry in China, the China National
Stroke Registry (CNSR), which was a nationwide, multi-
center, and prospective registry of consecutive patients
with acute cerebrovascular events [18]. Briefly, hospitals
in China are classified into three Levels: I (community
hospitals); II (hospitals that serve several communities);
and III (central hospitals for a certain district or city). A
Level III hospital is usually an academic center and more
medically advanced than level I and II hospitals. In total,
242 potential sites including 114 grade III, 71 grade II
and 57 grade I hospitals, from both urban and rural
areas, were initially identified by soliciting applications.
The CNSR steering committee evaluated the research
capability and commitment to the registry of each
hospital with a preliminary survey. Finally, a total of 132
hospitals including 100 Level IIIs and 32 Level IIs, which
cover 27 provinces and 4 municipalities across China,
were selected. Trained research coordinators at each
institute reviewed medical records daily to identify,
obtain consent and enroll consecutively eligible patients.
To be eligible for the study, subjects had to meet thefollowing criteria: (1) age 18 years or older; (2) hospital-
ized with a primary diagnosis of spontaneous ICH
according to World Health Organization criteria [19]
and with computed tomography (CT) confirmation; (3)
direct admission to hospital from a physician’s clinic or
emergency department; and (4) written informed con-
sent from patients or their legal representatives. Patients
were excluded if any of the criteria below were met: (1)
pre-stroke dependence (modified Rankin Scale score
≥3); (2) patients who did not agreed to participate in
follow-up; and (3) patients who were lost to one-year
follow-up. Due to the fact that documentation of
hematoma volume in the CNSR was not mandatory, for
this study, we also excluded patients whose admission
hematoma volume was not available. Eligible patients for
the study were randomly divided into derivation (60%)
and validation (40%) cohorts. The scientific use of data
registered in the CNSR was approved by the central
institutional review board at Beijing Tiantan Hospital
and local ethical committees. For a complete list of CNSR
investigators and ethical committees, see Additional file 1:
Appendix A and B.
Data collection and definition of variables
In the CNSR network, a standardized case report form
was used for data collection. The relevant data were
prospectively recorded. For this study, the following
candidate variables were analyzed: (1) demographics (age
and gender); (2) stroke risk factors: hypertension (history
of hypertension or anti-hypertensive medication use), dia-
betes mellitus (history of diabetes mellitus or anti-diabetic
medication use), dyslipidemia (history of dyslipidemia or
lipid-lowering medication use), atrial fibrillation (history
of atrial fibrillation or documentation of atrial fibrilla-
tion on admission), coronary heart disease, history of
stroke/transient ischemic attack (TIA), current smo-
king and heavy alcohol consumption (≥2 standard
alcohol beverages per day); (3) transportation mode to
hospital (by emergency medical system or private trans-
portation); (4) pre-admission medications: anticoagulation
treatment with warfarin, antiplatelet treatment and statins
use; (5) admission stroke severity based on the National
Institutes of Health Stroke Scale score (NIHSS) and the
Glasgow Coma Scale (GCS) score; (6) admission sys-
tolic and diastolic blood pressure (mmHg): (7) admis-
sion laboratory tests: hemoglobin, white blood cell
count, platelet count, blood glucose, and creatinine;
(8) neuroimaging variables: intracerebral hemorrhage
volume was measured using the ABC/2 method [20].
Hematoma location was classified as supratentorial or
infratentorial ICH. The presence or absence of intraven-
tricular extension was documented on the initial head CT
as well. All images were prospectively viewed by a trained
neuroradiologist blinded to clinical data at different study
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non-academic).
Functional outcome assessment
The modified Rankin Scale (mRS) was used to assess
functional outcome at one year after ICH. A central
follow-up blinded to baseline variables was made by
telephone interview by trained interviewers based on a
standardized interview protocol. Poor functional out-
come was defined as mRS ≥3 at one year after ICH.
Since different clinical care contexts or clinical research
studies may define poor outcome differently, we also ex-
amined discrimination of the ICH-FOS for one-year
functional outcome when mRS ≥4 and ≥5 were used to
define poor functional outcome.
Statistical analysis
Model building was performed exclusively in the deriv-
ation cohort. In univariate analysis, Chi-square and
Mann–Whitney tests were used as appropriate. Logistic
regression was used to determine independent predic-
tors for poor functional outcome at one year after ICH.
Candidate variables were those with a biologically plaus-
ible link to poor functional outcome after ICH on the
basis of prior publication or those associated with
poor functional outcome (mRS ≥3) on univariate ana-
lysis (P ≤0.1). On multivariable analysis, a backward
stepwise method was used to remove nonsignificant
variables from the model. To test for collinearity be-
tween the covariates of the final multivariable model,
the tolerance and variance inflation factor (VIF) of
each covariate was calculated. The β-coefficients from
the final model were used to generate the scoring
system of the ICH-FOS, as in previous studies
[21,22]. To derive an integer value, the β-coefficient
was multiplied by 4 and was rounded to the closest
integer. The resulting ICH-FOS was then validated by
assessing model discrimination and calibration in the
validation cohort [23]. Discrimination was assessed by
calculating the area under the receiver operating charac-
teristic curve (AUROC). Calibration was assessed by the
Hosmer-Lemeshow goodness-of-fit test and plot of obser-
ved versus predicted risk according to 10 deciles of the
predicted risk.
Furthermore, we compared discrimination of the ICH-
FOS and prior ICH scores for ICH outcomes in the
overall cohort. Because prior ICH scores were designed
for predicting ICH outcomes at different time points, in
this study, we compared discrimination of the ICH-FOS
and prior ICH scores with regard to 30-day, 3-month,
6-month, and 1-year poor functional outcomes (mRS ≥3)
and mortality after ICH. The primary criterion for selec-
tion of the model was whether all elements required for
the model were available in our dataset and, finally, eightexisting ICH scores met this criterion (original ICH score,
modified ICH score, Essen ICH score, ICH grading scale
(ICH-GS) score, FUNC score, modified ICH (MICH)
score, secondary ICH (sICH) score, and Landseed ICH
score). The AUROC and maximum Youden Index were
used to evaluate model discrimination. Pairwise AUROCs
were compared using Delong’s method [24] and sensitiv-
ity, specificity, positive predictive value (PPV) and negative
predictive value (NPV) were calculated at each ICH
score’s maximum Youden Index.
All tests were two-tailed and statistical significance
was determined at α level of 0.05. Statistical analysis was
performed using SAS 9.1 (SAS Institute, Cary, NC, USA),
SPSS 17.0 (SPSS Inc., Chicago, IL, USA), and Medcalc
software 12.3 (MedCalc®).
Results
Patient characteristics
Patient characteristics of the derivation and validation
cohorts are shown in Table 1. From September 2007 to
August 2008, 3,255 patients in the CNSR were eligible
for the study and were included in the final analysis
(Additional file 1: Figure S1 shows this in more detail). The
median age was 62 (interquartile range (IQR) 53 to 72) and
61.3% were men. A total of 1,497 (46.0%) had poor
functional outcome (mRS ≥3) at one year after ICH. The
eligible patients were randomly divided into derivation
(60%, n = 1,953) and validation (40%, n = 1,302) cohorts,
which were matched with respect to baseline characteris-
tics and one-year functional outcome after ICH (Table 1).
Clinical characteristics of patients included in the study
and those excluded for missing admission hematoma
volume (n = 881) are listed in Additional file 1: Table S1.
They were not statistically different in functional outcome
at one year after ICH.
Predictors of poor functional outcome at one year after ICH
The univariate analysis for potential predictors of poor
functional outcome (mRS ≥3) at one year after ICH in
the derivation cohort is shown in Additional file 1: Table
S2 and the multivariable predictors are listed in Table 2.
Age, admission NIHSS score, GCS score, blood glucose,
ICH location, hematoma volume and intraventricular
extension were identified as independent predictors for
poor functional outcome at one year after ICH. The
tolerance of covariates in the final multivariable model
ranged between 0.63 and 0.99; the mean VIF was 1.36
(range: 1.08 to 1.96).
Derivation of the ICH-FOS
The scoring system of ICH-FOS is listed in Table 3. The
median ICH-FOS was 4 (IQR: 2 to 7; range 0 to 15) in
the derivation cohort. For clinical practicability, we also
classified patients into five risk categories, which were
Table 1 Patient characteristics
Characteristics and outcomes Overall
(number = 3,255)
Derivation cohort
(number = 1,953)
Validation cohort
(number = 1,302)
P value
Demographics
Age, years, median (IQR) 62 (53–72) 62 (53–72) 62 (52–72) 0.12
Gender (male), n (%) 1995 (61.3) 1189 (80.9) 806 (61.9) 0.56
Risk factors, n (%)
Hypertension 2210 (67.9) 1338 (68.5) 872 (67.0) 0.36
Diabetes mellitus 290 (8.9) 179 (9.2) 111 (8.5) 0.53
Dyslipidemia 230 (7.1) 148 (7.6) 82 (6.3) 0.16
Atrial fibrillation 54 (1.7) 33 (1.7) 21 (1.6) 0.87
Coronary heart disease 204 (6.3) 123 (6.3) 81 (6.2) 0.93
History of stroke/TIA 889 (27.3) 543 (27.8) 346 (26.6) 0.44
Current smoker 1228 (37.7) 734 (37.6) 494 (37.9) 0.83
Heavy alcohol consumption 367 (11.3) 223 (11.4) 144 (11.1) 0.75
Transport to hospital by EMS, n (%) 1029 (31.6) 625 (32.0) 404 (31.0) 0.75
Pre-admission anticoagulation, n (%) 32 (1.0) 20 (1.0) 12 (0.9) 0.86
Pre-admission antiplatelet, n (%) 291 (8.9) 173 (8.9) 118 (9.1) 0.85
Pre-admission statin, n (%) 228 (7.0) 146 (7.5) 82 (6.3) 0.21
Admission NIHSS score, median (IQR) 9 (3–16) 9 (3–16) 9 (3–17) 0.98
Admission GCS score, median (IQR) 14 (9–15) 14 (9–15) 14 (9–15) 0.51
Admission SBP (mm Hg), median (IQR) 160 (147–180) 160 (147–180) 160 (146–180) 0.17
Admission DBP (mm Hg), median (IQR) 95 (87–106) 94 (87–105) 96 (87–108) 0.13
Admission WBC, 109/L, median (IQR) 8.7 (6.7-11.3) 8.6 (6.7-11.2) 8.8 (6.7-11.6) 0.37
Admission hemoglobin, g/dL, median (IQR) 139 (126–150) 139 (126–150) 139 (127–150) 0.72
Admission platelet, 109/L, median (IQR) 186 (145–230) 187 (143–232) 185 (147–227) 0.83
Admission glucose (mmol/L), median (IQR) 6.3 (5.7-7.5) 6.3 (5.7-7.5) 6.3 (5.7-7.5) 0.58
Admission creatinine (mmol/L), median (IQR) 77.0 (62.0-92.0) 77 (62–92) 76 (61–92) 0.39
Infratentorial ICH, n (%) 393 (12.1) 229 (11.7) 164 (12.6) 0.46
Hematoma volume (cm3), median (IQR) 12.6 (5.5-28.0) 12.8 (5.2-28.1) 12.3 (5.7-28.0) 0.93
Intraventricular extension, n (%) 962 (29.6) 587 (30.1) 375 (28.8) 0.44
Withdrawal of medical care, n (%) 404 (12.4) 247 (12.6) 157 (12.1) 0.63
Academic hospital, n (%) 1724 (53.0) 1043 (53.4) 681 (52.3) 0.55
Surgical treatment 81 (2.5) 50 (2.6) 31 (2.4) 0.82
mRS score at one year after ICH, n (%) 0.73
mRS = 0 691 (21.2) 409 (20.9) 282 (21.7)
mRS = 1 743 (22.8) 442 (22.6) 301 (23.1)
mRS = 2 324 (10.0) 190 (9.7) 134 (10.3)
mRS = 3 318 (9.8) 196 (10.0) 122 (9.4)
mRS = 4 238 (7.3) 134 (6.9) 104 (8.0)
mRS = 5 92 (2.8) 56 (2.9) 36 (2.8)
mRS = 6 849 (26.1) 526 (26.9) 323 (24.8)
DBP, diastolic blood pressure; EMS, Emergency Medical System; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; IQR, interquartile range; mRS, modified
Rankin Scale; NIHSS, National Institutes of Health Stroke Scale score; SBP, systolic blood pressure; TIA, transient ischemic attack; WBC, white blood cell count.
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Figure 1A and 1B show the proportion of poor func-
tional outcome at one year after ICH according to theICH-FOS score and risk categories in the derivation and
validation cohorts, respectively. The magnitude of the
ICH-FOS score had prognostic implications.
Table 2 Multivariable predictors of poor functional outcome (mRS ≥3) at one year after ICH in the derivation cohort
(number = 1953)
Variables β-coefficients SE Adjusted ORa 95% CI P value
Model intercept −5.855
Age (per year increase) 0.051 0.004 1.05 1.04–1.06 <0.001
Admission NIHSS score (per 1 increase) 0.092 0.006 1.10 1.08–1.11 <0.001
Admission GCS score (per 1 decrease) 0.093 0.014 1.09 1.07–1.12 <0.001
Admission blood glucose (per 1 mmol/L increase) 0.075 0.023 1.08 1.03–1.13 0.001
Infratentorial location of ICH (yes) 0.705 0.136 2.02 1.55–2.65 <0.001
Hematoma volume (per 1 cm3 increase) 0.018 0.002 1.02 1.01–1.03 <0.001
Intraventricular extension (yes) 0.486 0.100 1.62 1.34–1.98 <0.001
aMultivariable logistic regression adjusted for age, gender, stroke risk factors, transportation mode to hospital, pre-admission anticoagulation, antiplatelet and
statins use, admission NIHSS score, GCS score, laboratory tests on admission (hemoglobin, white blood cell count, platelet count, blood glucose and creatinine),
ICH location, hematoma volume, intraventricular extension and hospital academic status. CI, confidence interval; GCS, Glasgow Coma Scale; ICH, intracerebral
hemorrhage; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale score; OR, odds ratio; SE, standard error.
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The performance of the ICH-FOS (AUROC) in the der-
ivation and validation cohort was 0.836 (95% CI = 0.819
to 0.854) and 0.830 (95% CI = 0.808 to 0.852), res-
pectively. Similar good discrimination was found when
mRS ≥4 and mRS ≥5 was used to define poor functional
outcome at one year after ICH (Additional file 1: Table
S3 shows this in more detail). The Hosmer-Lemeshow
test was not significant in the derivation (P = 0.42) and
validation (P = 0.39) cohorts; meanwhile, the predicted
and observed risk of poor functional outcome at one
year after ICH was highly correlated (Additional file 1:
Figure S2 shows this in more detail).
Sensitivity analysis
We completed prespecified subgroup analyses by age,
gender, hematoma location, status of medical care
withdrawal and hospital academic status. Similar good
discrimination was seen in these subgroups (Additional
file 1: Table S4 shows this in more detail). When patients
with missing admission ICH volume (n = 881) were in-
cluded in analysis and coded as median ICH volume
(12 cm3), the ICH-FOS showed good discrimination
(AUROC: 0.827; 95% CI: 0.814 to 0.839) for one-year poor
functional outcome (mRS ≥3) after ICH. The ICH-FOS also
demonstrated good discrimination when patients lost to
follow up (n = 281) were included and coded as having
good functional outcome (mRS ≤2) (AUROC: 0.817; 95%
CI: 0.803 to 0.832) or poor functional outcome (mRS ≥3)
(AUROC: 0.822; 95% CI: 0.807 to 0.836).
Comparative evaluation of ICH scores
Figure 2 shows the discrimination of the ICH-FOS and eight
existing ICH scores with regard to poor functional outcome
(mRS ≥3) and mortality at 30 days, 3 months, 6 months and
1 year after ICH in the overall cohort (n = 3,255) (Additional
file 1: Tables S5, S6, S7, S8 show this in more detail). For30-day poor functional outcome, AUROCs ranged from
0.735 to 0.837. The ICH-FOS and Essen ICH score had
comparable AUROCs, which were significantly higher than
those of other scores. For 30-day mortality, AUROCs ranged
from 0.793 to 0.836. The ICH-FOS had the highest
AUROC, although there was no significant pairwise differ-
ence in AUROC between ICH-FOS and the original ICH
score and ICH-GS score. For three-month poor functional
outcome, ICH-FOS and Essen ICH score were demon-
strated to be significantly superior to other scores. For
three-month mortality, six-month poor functional outcome,
six-month mortality, one-year poor functional outcome and
one-year mortality, the ICH-FOS consistently showed the
highest AUROC and maximum Youden Index and associ-
ated PPV and NPV. The pairwise difference in AUROC be-
tween ICH-FOS and eight existing ICH scores was
statistically significant (all P <0.001).Discussion
In this study, we developed and validated a risk score for
predicting one-year functional outcome after ICH using in-
formation routinely available at presentation. A 16-point
ICH-FOS was developed from the set of independent pre-
dictors of one-year poor functional outcome (mRS ≥3) after
ICH. The ICH-FOS showed good discrimination and cali-
bration in both the derivation and validation cohorts regar-
dless of the specific cutpoint of mRS (mRS ≥3, ≥4, ≥5 or = 6)
used to define poor outcome. This is important since differ-
ent clinical care contexts or clinical research studies may de-
fine poor outcome differently. When compared to eight
existing scores, the ICH-FOS showed significantly better dis-
crimination for poor functional outcome and mortality at
one year after ICH. Meanwhile, the ICH-FOS also demon-
strated either comparable or significantly better discrimin-
ation for 30-day, 3-month, and 6-month poor functional
outcome and mortality after ICH than eight existing scores.
Table 3 Point scoring system of the ICH Functional
Outcome Score (ICH-FOS)
Items Score
Age group
≤59 0
60 to 69 1
70 to 79 2
≥80 4
Admission NIHSS score
0 to 5 0
6 to 10 2
11 to 15 3
16 to 20 4
≥21 5
Admission GCS score
15 to 13 0
9 to 12 1
3 to 8 2
Admission glucose (mmol/L)
≤11.0 0
≥11.1 1
ICH location
Supratentorial 0
Infratentorial 1
ICH volume
For supratentorial location
<40 ml 0
40 to 70 ml 2
>70 ml 2
For infratentorial location
<10 ml 0
10 to 20 ml 2
>20 ml 2
Extension into ventricles
No 0
Yes 1
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decision-making during acute hospitalization and post-
discharge, we used only patient characteristics available
at presentation. We chose not to include variables re-
lated to in-hospital and postdischarge management, such
as neurosurgical intervention [25,26], treatment location
(in stroke unit [27] or neurocritical care unit [28,29]),
withdrawal of medical care [30,31] and rehabilitation,
despite the fact that these factors might influence
functional outcome at one year after ICH. This model,therefore, predicts the expected outcome at one year
after ICH at presentation.
During the past decade, several prognostic models have
been developed for ICH. In 2001, Hemphill et al. [6] intro-
duced the original ICH score (oICH), which is one of the
first simple and easily assessable clinical grading scales for
ICH. Since then, a number of modifications to oICH [7,8]
and other pragmatic ICH scores [7,9-16] have been pro-
posed. Although some of these ICH scores have been in-
ternally or externally validated, none of them has been
universally accepted and consistently used in routine clinical
practice and clinical research [5]. For a clinical grading scale
to become widely used and effective, it must be reliable, ac-
curate and practical. The ICH-FOS is different from the
compared ICH scores in several aspects: First, for reliability,
the ICH-FOS was developed based on the largest derivation
(n = 1,953) and validation (n = 1,302) cohorts, which in-
cluded consecutive ICH patients who were outside of cli-
nical trial and were more representative of real-world
clinical practice. Additionally, sensitivity analysis showed
that the ICH-FOS was robust against medical care with-
drawal and was effective for ICH patients of different ages,
gender and hematoma location. Second, for accuracy, the
ICH-FOS demonstrated good discrimination and calibration
with regard to one-year poor functional outcome and mor-
tality after ICH in the derivation and validation cohorts. Fi-
nally, for practicality, the ICH-FOS consists of factors that
are readily available at presentation. In addition, by a simple
score, patients can be easily stratified into five risk categor-
ies, which might be useful for both routine clinical practice
and clinical research.
With several ICH related risk-stratification and prog-
nostic models available, identification of the most accur-
ate and reliable grading scale(s) would be of great value
to patients, clinicians, and researchers. In this study, we
compared the discrimination of the ICH-FOS and eight
existing ICH scores with regard to both poor functional
outcome (mRS ≥3) and mortality at 30 days, 3 months,
6 months, and 1 year after ICH in a large cohort. For
one-year poor functional outcome and mortality, the
ICH-FOS was shown to be significantly better than eight
prior ICH scores. Meanwhile, the ICH-FOS also demon-
strated either comparable or significantly better discri-
mination for ICH outcomes at 30 days, 3 months and
6 months after ICH. Although promising, caution has to
be taken when interpreting the results: first, the study
populations for derivation and validation of these ICH
scores are different. The baseline characteristics of our
study were different from those of western cohorts used
to develop prior ICH scores [6,9-11], such as younger age of
ICH onset, less severity of neurological deficit, smaller
hematoma volume on admission and fewer intraventricular
extensions in our study. It is not our primary aim to com-
pare the differences of these ICH cohorts and it is hard to
Figure 1 Functional outcome at one year after ICH according to the ICH-FOS score and risk category. Showing the proportion of poor
functional outcome (mRS ≥3) at one year after ICH according to the ICH-FOS score (A) and risk category (B) in the derivation and validation co-
horts, respectively. The risk of poor functional outcome increased steadily with higher ICH-FOS score. Error bars indicated 95% confidence
interval of the proportion of poor functional outcome at one year after ICH for each ICH-FOS score or risk category. ICH-FOS, Intracerebral
Hemorrhage Functional Outcome Score; mRS, modified Rankin Scale.
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study population. Second, there might be complex genetic,
social, cultural, and economic factors as well as regional
management philosophies and preferences that are difficult
to account for when grading scales are developed or applied
to a distinct population. Finally, the intended outcome
(functional outcome versus mortality), outcome assessent
methods (glasgow outcomes scale GOS versus barthel index
BI versus mRS), and timing of follow-up (in-hospital versus
30-day versus 3-month versus 6-month versus 1-year after
ICH) are different for these existing ICH scores. In the fu-
ture, the standardization of these variables would greatly fa-
cilitate validation and comparison of ICH grading scales [5].Despite advances in medical knowledge, treatment of
ICH remains strictly supportive with not many evidence-
based interventions currently available. This might be
at least partially due to inclusion of patients with
unbalanced, too high, or too low risk of developing poor
functional outcome and mortality in prior studies. Al-
though there was a statistically significant difference, our
study showed that the ICH-FOS and several other ICH pre-
dictive tools, such as the Essen ICH score, the ICH-GS
score and the original ICH score were clinically useful in
stratifying patients according to the potential risk of poor
functional outcome or mortality. Thus, clinicians and cli-
nical researchers have a great deal of flexibility in their
Figure 2 Comparative evaluation of the ICH-FOS and existing ICH scores. Showing the discrimination of the ICH-FOS and eight existing ICH
scores with regard to poor functional outcome (mRS ≥3) and mortality at 30 days, 3 months, 6 months, and 1 year after ICH in the overall cohort
(n = 3,255). ICH-FOS, Intracerebral Hemorrhage Functional Outcome Score; mRS, modified Rankin Scale.
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and preference. It is expected that randomized controlled
ICH efficacy trials with stratification of patients’ potential
long-term prognosis will be conducted in the future.
Our study has limitations that deserve comment. First,
like all observational studies, we cannot rule out the possi-
bility that additional variables (unmeasured confounders)
might be predictive of long-term functional outcome after
ICH. In the future, novel biochemical [32], neuroimaging
[33] or genetic markers might be identified and would im-
prove the discrimination of our model. Second, admission
blood glucose and hematoma volume were associated with
one-year functional outcome after ICH in a continuous
manner. However, for clinical practicability, they were cate-
gorized and this inevitably led to loss of information. Fur-
thermore, it is possible that the cutoff value may vary with
the development of our knowledge of ICH pathophysiology,
especially for blood glucose. Third, Intraventricular
hemorrhage (IVH) was dichotomized into present or absent
as opposed to the use of IVH volume. Fourth, due to the
fact that Graeb score and admission body temperature were
not routinely collected in the CNSR, we cannot externally
validate two prior ICH scores (the mICHs [8] and new ICHscore [7]) in this study. Another two ICH scores were also ex-
cluded because they focused on a specific subgroup of pa-
tients (ICH patients with hemodialysis [13] and known
hypertension [16]). Finally, both the derivation and vali-
dation cohorts originated from an Asian population and
the ICH-FOS needs to be further validated in different
populations.
Conclusions
The ICH-FOS is a valid clinical grading scale for predicting
functional outcome at one year after ICH. Further studies to
validate the ICH-FOS in different populations are needed.
Key messages
 Age, admission NIHSS score, GCS score, blood
glucose, ICH location, hematoma volume and
intraventricular extension were identified as
independent predictors for poor functional outcome
(mRS ≥3) at one year after ICH.
 A 16-point ICH-FOS was developed from these
independent predictors of one-year poor functional
outcome (mRS ≥3) after ICH.
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http://ccforum.com/content/17/6/R275 The ICH-FOS showed good discrimination and
calibration in large derivation (n = 1,953) and
validation (n = 1,302) cohorts.
 The ICH-FOS also demonstrated comparable or
significantly better discrimination with regard to
30-day, 3-month and 6-month poor functional
outcome (mRS ≥3) and mortality when compared
to eight existing ICH scores.
 Further validation of the ICH-FOS in different
populations is needed.
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